Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
暂无分享,去创建一个
H. Scott | S. Branford | M. Ho | W. Parker | T. Hughes
[1] H. Scott,et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Martin C. Müller,et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.
[3] H. Kantarjian,et al. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy , 2011, Haematologica.
[4] R. Foà,et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis , 2011, Haematologica.
[5] J. Radich,et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). , 2010, Blood.
[6] J. Melo,et al. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? , 2009, Blood.
[7] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Martin C. Müller,et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. , 2009, Blood.
[9] M. Baccarani,et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. , 2009, Blood.
[10] Martin C. Müller,et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib , 2009, Haematologica.
[11] Martin C. Müller,et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Larson,et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Rocco Piazza,et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Janusz Blasiak,et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. , 2008, Cancer research.
[15] T. Skorski,et al. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress , 2008, Leukemia.
[16] J. Radich,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.
[17] B. Quesnel,et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism , 2008, Leukemia.
[18] C. Sawyers,et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.
[19] M. Baccarani,et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.
[20] M. Baccarani,et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.
[21] Carissa A. Sanchez,et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.
[22] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[23] T. Skorski,et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. , 2004, Blood.
[24] T. Skorski,et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. , 2003, Blood.
[25] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[26] Mary R. Myerscough,et al. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions , 2007, Clinical & Experimental Metastasis.